About Reprise Biomedical
Reprise Biomedical is a company based in Plymouth (United States) founded in 2019.. Reprise Biomedical has raised $29.42 million across 4 funding rounds. The company has 16 employees as of December 31, 2022. Reprise Biomedical offers products and services including Miro3D, MiroDry, MiroTract, MiroDerm, and MiroFlex. Reprise Biomedical operates in a competitive market with competitors including MiMedx Group, pacifymedical, Hans Biomed, Rapid Graft and 3D Global Biotech, among others.
- Headquarter Plymouth, United States
- Employees 16 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$29.42 M (USD)
in 4 rounds
-
Latest Funding Round
$6.36 M (USD), Series B
Jun 26, 2025
-
Investors
-
Employee Count
16
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Reprise Biomedical
Reprise Biomedical offers a comprehensive portfolio of products and services, including Miro3D, MiroDry, MiroTract, MiroDerm, and MiroFlex. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Three-dimensional solution for deep and tunneling wound healing.
Device for managing advanced and complex wounds.
Product designed for targeted delivery to tunneling wounds.
Biologic matrix for skin wound repair and integration.
Flexible scaffold using decellularization for wound treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of Reprise Biomedical
Reprise Biomedical has successfully raised a total of $29.42M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $6.36 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $6.4M
-
First Round
First Round
(25 Nov 2020)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Series B - Reprise Biomedical | Valuation |
investors |
|
| Jan, 2023 | Amount | Series B - Reprise Biomedical | Valuation |
investors |
|
| Mar, 2021 | Amount | Series A - Reprise Biomedical | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Reprise Biomedical
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Reprise Biomedical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Reprise Biomedical Comparisons
Competitors of Reprise Biomedical
Reprise Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MiMedx Group, pacifymedical, Hans Biomed, Rapid Graft and 3D Global Biotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
|
|
| domain | founded_year | HQ Location |
Skin-spraying devices for advanced wound care are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Allograft tissues, biomaterials, and skin cell treatments are developed.
|
|
| domain | founded_year | HQ Location |
Split-skin grafts are developed for chronic wound treatment.
|
|
| domain | founded_year | HQ Location |
Developer of human tissues and organ reconstructed implants
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Reprise Biomedical
Frequently Asked Questions about Reprise Biomedical
When was Reprise Biomedical founded?
Reprise Biomedical was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is Reprise Biomedical located?
Reprise Biomedical is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
Who is the current CEO of Reprise Biomedical?
Carrie Powers is the current CEO of Reprise Biomedical.
Is Reprise Biomedical a funded company?
Reprise Biomedical is a funded company, having raised a total of $29.42M across 4 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Nov 25, 2020.
How many employees does Reprise Biomedical have?
As of Dec 31, 2022, the latest employee count at Reprise Biomedical is 16.
What does Reprise Biomedical do?
Developer of surgical mesh for wound management. The products developed are FDA-approved MIRODERM (derived from the porcine liver) and MIROMESH (non-crosslinked acellular surgical mesh) that uses perfusion decellularization technology. It is used to treat wounds, ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled and undermined wounds, trauma wounds, drainage wounds, and surgical wounds.
Who are the top competitors of Reprise Biomedical?
Reprise Biomedical's top competitors include MiMedx Group, pacifymedical and Hans Biomed.
What products or services does Reprise Biomedical offer?
Reprise Biomedical offers Miro3D, MiroDry, MiroTract, MiroDerm, and MiroFlex.